go that progress. today, had an in growth. morning, Biogen great we made I Biogen's pleasure once substantial year and time, that get year, to earning -- greater the we ago, growing, positive occasions, a can of growth it the At of sustainable which expressed And detail, announce said we will the company of that for can I earnings we you, will Chuck. future. to really a per presenting everybody. as earnings says which first objective number a expecting we the on amount intervening see return prior are A Biogen see time. we've Biogen into in Mike Thank of share -- Good quarterly results the And opportunity growth.
And have is guidance, I for we foreseeable think becoming
don't with measures things. those patent coming those And little think soon in I no portfolio. review if just current we for We any that number a have And repositioned of our reduction really of We other have, have expiries fact, new known. are already act Biogen I other very to some undertaken really that growth. than exposure inflation we've anytime in
sclerosis awful since that for franchise first the -- industry. stalwart particular, was XX highest our of really The year. of company required years last launches. change. refocus been anyone approvals That's multiple in FDA is from The company product from X the the had quite -- has to new new our the -- second cultural drivers, on launches an inception, And product growth ago. Biogen our of in lot its
leader physicians and we the Our people the still this sclerosis, are patients are and passionate multiple in who multiple about market have to treat space. sclerosis the
we that and competition, facing is to is categories and new have increasing that a therapeutic businesses. franchise However, new embrace
LEQEMBI, focus, And QALSODY. particularly shift in have ZURZUVAE,SKYCLARYS towards resources really and a so had major and we
of modest demonstrating teams our forecast product We growth. that forecast still is I products decline also, to with had can protection, would if even product patent -- products this competition. competitive product of actually a analyst could like shown though, administration again, this some advantage. bring particularly and have substantial back a And be with mode they that of SPINRAZA, take Obviously, proud the
a if be the And what value Biogen of support is evidence more that SPINRAZA extremely develop infusion of some be continues pill, products. to that these see being really most proposition So efficacy in important we at have good still factor. an devastating you're example. a this a in the segment. is medical leader if going to you for lot But you to And preferred why its to is have able diseases, the than is
business. cost industry, address cost. got that. the of We the categories the capabilities. new reengineer that highest management We organization, just many wanted company, therapeutic reducing into needed about you shifting took we of of came but We entering focus to me to number to and you've think about were agility the of in have. but we our told the a I We one needed of we when our layers -- think around it and As portfolio, first you've got bases the product to mature steps wasn't
so realize of end track extremely and $XXX look savings half interesting we we're by at to of That's, gross XXXX. the Fit-for-Growth of an We've savings achieved then And we And had to approximately savings, on a million billion. And $XXX reengineering project. and is development. the Biogen company. research of of $X implemented course, already net a million of
-- often targets in really to where try Biogen diseases devastating And course, by we pioneering is are solutions of find there's we disease and that underlying understand of the do doing biology these because go of conditions. fact diseases. that the don't target and nobody else the we diseases for lot But of that a that. we All pride pioneering, really
can a need up quite do risk in be really yet lot And taking our we so end expensive. and company we Biogen these of like And a trials world.
development to manage has of products objective we investments our the course, focus and in will portfolio. on impact. the so And greatest the have those that research been have really And to risk
to growing investors. sustainably as go and invest one company and to projects. attractive in is new capital have a need to We the which Biogen have We
I so with Prius we've and an been [ the view able Health take ], to think pipeline. of extremely disciplined objective And
Pia on rethink about that.
And again, at that important that but we year, change Priya go this illnesses, next we more and readouts data at our changed into year, pipeline how extremely looking do how be research efforts. talk X done we do have science, to in as we lot reinforce will kind of going we're We necessarily haven't Biogen. A has
think development research continue think I to And of and be So for to Biogen. the I growth important source a extremely is future.
and I'll look not to are again, that, what we does growth, remind at just as commercial. clearly, everybody have. and we science And pioneering we Now drive pioneering
impact disease product. the benefit the study are this was data showed CLARITY in at we the reducing you and talk efficacy, and some to that failed CTAD in on the main we we that we the things cognition. of about convincingly the about first believe lot a in to actually, was because interesting you importance we patient. recover. is it talk product, that But going about, drugs, demonstrate we're the right the of weren't about the that a across a barrier, we really the demonstrate plaque know right that or cases, business if in environment neurons efficacy an we're is you're to to injured which you're patient. we're efficacy really enough of -- the even where protect our the likely can invested talking characteristic fact, when But drug greater at of Alzheimer's of looking of And create for earlier not And the that. you One can X there industry show decades, go, couldn't were disease. get more neurons in trying in One with blood-brain in problems
by patients. in plaque at happens looking make you what have we to huge investing remove and so AHEAD a study maintenance. We're in at And this trying more having a our the formulation. for investment convenient subcutaneous We're when to look patients presymptomatic
so pioneering also in and the are into in are system continues, today Patients system. the is marketplace. And and -- the coming Alzheimer's the out not there the with this pioneering
patients got So the on at we've approximately therapy moment. X,XXX
registries. access have the don't we direct as Now companies patient to
in an we you are about we When seeing but indication we have But we about as at are was look out of we're about far report in week on perfect patients as can we information like the analyst X,XXX information, been CMS latest not able a registry know is month And other of getting all There And that that's to January. have X,XXX suggests few increase registry. the X the that seen analysts that were Altinet on [ XXX what over the patients December. example. of this have access You there ], XX% per data. tell, a there last for have, patients there that again, registries some and registry. about XXX, as that, week
positive place product. who PET is the We're activity talk have P&T are demand the volume. reporting we of that care IDNs is moving clearly to seeing doing the actually LEQEMBI. are improve put if IDNs committee had of we clearly that scans, the seeing to XXX people in XX% diagnostics, pathways people have the treatment blood decisions. But the everybody the increased are now out and ordered those the access. who protocols sell XX So top and there for MRIs, the to
are they least you patients so saw fourfold three belief at results, and is those their who rooms. for or the actually in with waiting all as of And Eisai's -- treatment, that on are
So And now solid believe promotion the we and very we pathways increase we making model. we progress. it's with to also And enough our place, have time reimbursement believe now that validated there. level that believe of go-to-market in we're IDNs out do we have care
total seen visit Japan. I once approved for seen meeting, And validated, China, by And model and our announced, alongside And this Biogen had the And previously it's and proud there was we course, we've force last in from as now be that the for physicians. so launch launch XX%. of time Biogen working as agreed launch on be that year very already was is be colleagues really Japan. expanding Eisai has year. go-to-market we've the LEQEMBI colleagues for that also and go field will launch to about in later to Eisai we the in will U.S.
So have with before, really and said This we are making is, everywhere we analog. launch a progress. doesn't an have as we look solid that LEQEMBI,
a both be and seeing. fact we're patients results. have would believe progressive importance to of the we this ramp We that guided investors And our what that's long-term in and financial the continue always to to to LEQEMBI
on Moving SKYCLARYS. to
numbers launch You've the seen the U.S. for
We have patients therapy. a have indication pediatric now yet. on about X,XXX don't We
about X,XXX. population So potential the is
lot a a lot I And diseases. of think on therapy awful strength. months of an we've XX% over cement. Biogen an X got There's is these complexity this little launch, lot the has of rare about launching There's within So of awful patients in where
to and from we able so can of the reduce in form to support terms about got start coverage there have reimbursement. of there. out shipment And their the And already course, We've been patients time that demonstrate of out awful X/X an lot XX%. need physicians we by
and And patients patient pathways. the access managers so have physicians family services assisting to who navigate we are and care
One expect model that to we we the about of of for by the night, Commission formal the that in SPINRAZA ex-U.S., Last European with U.S. SKYCLARYS. and be is sales the a do SKYCLARYS. that we see our for X/X we things announced approval X/X and
program in including of up we a and are those those in European number outside We access countries, U.S. have setting countries, of of the process the in the expanded
And postpartum that that million. seek is excess X unmet to indication health, SKYCLARYS. all in studies from This today. benefit need.
Tremendous for on to and to the obtain about strategy maternal get $X.X the We treatment to XX,XXX course, often talking actively underway We're health. needed in mental talking be those our It diagnosed year, been be about treatment. filing has sure and we every children patients working we're incidence way trends estimated with key about are depression difficult of have under can of also from that Friedreich’'s societies but the make are are doing men would believed others is global And enormous [indiscernible], ataxia coverage. media age a
initial of it's awful weeks really launch to the there's very expectations to say lot work of promising. who depression. data. above of indications an have are suffering and outreach But well from So get to X do are postpartum women I to
is We think to depressive conclusions. depression So this been appreciative highly demand. with of everything major were that are we payers. I come But place. and say And that positive. positioning really that have is I'm to to prescriptions also go honoring see because product helping I actually data meant seeing back I more they contracting to all and any have recontract think haven't extremely got of we pivoted even disorder, firm want to payers actually we with to we had we've for in our postpartum though originally
I'll So start it for Increasingly, what like selling, we're Priya to patients because turn is the about with what talk coming to think but we'd our that's to that, out only of hope new over not pipeline. also
turn So I'll over that you, Priya. to
